Eurofins Discovery supports COVID-19 research

By The Science Advisory Board staff writers

April 13, 2020 -- Eurofins Discovery has announced that it aims to accelerate COVID-19 antiviral drug discovery research.

Researchers are exploring treatment strategies for the disease that include targeting angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and the SARS-CoV-2 main protease, as well as large molecule therapies, the company said.

Eurofins Discovery offers these researchers the following services:

  • Bioassays and target specific assays
  • Custom assay development
  • Cytokine storm assessment
  • Drug repositioning services
  • Efficacy testing
  • Safety profiling


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.